Business Context and Reporting Period
This Form 8-K filing by Bioaffinity Technologies, Inc. (BIAF) was submitted on February 7, 2025. The report addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the company's compliance with continued listing standards.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on stock listing status.
Material Changes
The material event reported is the failure of the Company's common stock to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days (December 23, 2024, through February 6, 2025), violating Nasdaq Listing Rule 5550(a)(2).
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial compliance period of 180 calendar days, ending on August 6, 2025, to regain compliance.
- Remediation Path: Compliance can be achieved if the closing bid price remains at or above $1.00 for a minimum of ten consecutive business days during the compliance period.
- Secondary Compliance Option: If the price requirement is not met by August 6, 2025, the Company may be eligible for an additional compliance period if it meets the market value of publicly held shares requirement and all other initial listing standards.
- Management Action: Management intends to actively monitor the bid price and consider available options to regain compliance. The notice has no immediate effect on trading, and the stock will continue to trade under the symbol "BIAF."
Investor Verification Checklist
- Verify the current closing bid price of BIAF stock relative to the $1.00 threshold.
- Monitor the stock price for a sustained period of 10 consecutive business days above $1.00 to confirm compliance.
- Review the Company's market value of publicly held shares to assess eligibility for a second compliance period if the initial deadline is missed.
- Check for future announcements regarding reverse stock splits or other corporate actions intended to address the bid price deficiency.